盐酸多奈哌齐片人体生物等效性研究

目的进行试验制剂盐酸多奈哌齐片与参比制剂安理申的生物等效性试验,为新药报批及其临床应用提供试验依据.方法用单剂双交叉试验,健康志愿者18名,分别于试验当日晨空腹一次口服试验制剂盐酸多奈哌齐片和参比制剂安理申10mg,采用高效液相色谱法测定盐酸多奈哌齐经时血浓度.结果试验制剂盐酸多奈哌齐片和参比制剂主要药代动力学参数t1/2(β)分别为(54.28±10.14)h和(53.53±9.919)h,Tpeak分别为(3.50±1.15)h和(3.0±1.125)h,Cmax分别为(87±17)ng/mL和(99±23)ng/mL,AUC0～t分别为(2719±1124)ng/mL·h和(3127±1299)ng/mL·h,AUC0～∞分别为(3072±1324)ng/mL·h和(3525±1517)ng/mL·h.试验制剂盐酸多奈哌齐片相对生物利用度为(103.34±14.29)%.结论盐酸多奈哌齐片与参比制剂安理申具有生物等效性,为生物等效制剂.     

离子对-反相高效液相色谱法测定布洛伪麻分散片的含量

目的:建立布洛伪麻分散片含量的测定方法.方法:色谱柱为Kromasil C18柱(4.6 mm×150 mm,5 μm),流动相为醋酸-醋酸钠缓冲液:乙腈(4:6),每1 000 mL流动相溶解十二烷基硫酸钠1.0 g;检测波长为257 nm.结果:布洛芬和盐酸伪麻黄碱含量测定的线性范围分别为0.8～8 mg/mL(r=0.999 8)和0.12～1.2 mg/mL(r=0.999 9),平均回收率分别为101.7%(RSD=0.53%,n=9)和100.2%(RSD=0.8%,n=9).结论:该方法简便、重现性好,适用于布洛伪麻分散片的质量控制.     

愈美分散片的HPLC测定

建立了HPLC法测定愈美分散片中愈创木酚甘油醚和氢溴酸右美沙芬的含量.采用ODS柱,流动相为乙腈-甲醇-0.01%三乙胺溶液(18:15:67,pH3.5),流速1.0ml/min,检测波长276nm.愈创木酚甘油醚和氢溴酸右美沙芬的线性范围分别为6～72μg/ml和4.2～51μg/ml,平均回收率分别为99.0%和102.6%,RSD分别为1.2%和1.5%.     

复方杜仲片质量标准研究

目的完善复方杜仲片的质量标准.方法对方中的牛膝、益母草进行TLC鉴别,对黄芩采用HPLC法定量,色谱条件为Kromasil-C18柱,以甲醇-水-磷酸(45:55:0.2)为流动相;检测波长为315 nm;流速1.0 mL·min-1.结果在选定的薄层条件下,牛膝、益母草的薄层图谱清晰,分离度好.黄芩苷在0.537 66～2.688μg范围内具有良好的线性关系,其回归方程为:A=39 094.51 C-800.14,r=0.999 9.平均回收率为96.5%,RSD=2.1%.结论实验方法操作简单,可以用来控制本制剂质量.     

中心组合设计优化法筛选独一味分散片制备工艺

 目的　中心组合设计法优化独一味分散片制备处方。方法　采用粉末直接压片,以分散片崩解时间、木犀草苷溶出的t₈₀及分散片混悬后的混悬系数为考察指标,应用中心多点等距设计法及效应面优化法对独一味分散片处方进行筛选,通过对自变量各水平的多元线性回归及二项式拟合,选取较佳工艺,并进行预测分析。结果　考察指标与各因素间具有较好的相关性,优化后独一味分散片处方为12％PVPP为崩解剂、14％预胶化淀粉为溶胀剂、3％微粉硅胶为润滑剂和助流剂、45％MCC为填充剂。优化条件下制备的分散片崩解时间为20.6s,木犀草苷溶出的t₈₀为1.68 min,分散片混悬后的混悬系数为0.068 9。结论 中心组合设计法具有应用简便、预测性好等优点,筛选的处方可以在最适宜的范围内制备一定硬度且具有可被接受口味的速释分散片。     

反相高效液相色谱法测定风湿骨康片中士的宁的含量

目的:建立RP-HPLC法测定风湿骨康片中士的宁的含量,完善质量标准.方法:采用Hyper-C18柱,0.03mol·L-1甲酸溶液(用三乙胺调节pH至3.0±0.1)-乙腈(78∶22)为流动相,254nm为检测波长.结果:测得线性范围0.416μg～4.992μg(r=0.9998),平均回收率98.65%,RSD为1.88%(n=5).结论:本法简便,准确,专属性强.     

甲磺酸加替沙星片治疗急性细菌性感染的细菌学疗效

目的评价甲磺酸加替沙星片治疗急性细菌性感染疾病的细菌学疗效. 方法以盐酸左氧氟沙星片为对照药,采用多中心随机盲法阳性对照平行试验设计方法,评价甲磺酸加替沙星片治疗急性细菌性感染的细菌学疗效. 结果甲磺酸加替沙星片组和盐酸左氧氟沙星片组细菌分离阳性率分别为77.42%和80.99%;两组细菌清除率分别为 97.92%和97.96%;对不同致病菌感染有效率分别为83.33%～100%和80%～100%;以上结果两组差异无统计学意义;纸片药敏试验结果表明加替沙星、左氧氟沙星、氧氟沙星、环丙沙星和司帕沙星的细菌敏感率分别为93.81%、93.30%、91.24%、84.54%和87.11%;从MIC90结果看,加替沙星对多数致病菌的抗菌活性略强于左氧氟沙星. 结论甲磺酸加替沙星片具有良好的细菌学疗效.     

健胃愈疡片联合三联疗法治疗反流性食管炎

【摘要】 目的 探讨健胃愈疡片联合三联疗法治疗反流性食管炎的临床疗效。方法 选择2015年2月~2017年2月我院接诊的90例反流性食管炎患者,通过随机数表法分为观察组和对照组各45例,在基础治疗上,对照组给予三联疗法（奥美拉唑+甲硝唑+阿莫西林）治疗,观察组联合健胃愈疡片治疗,两组均连续治疗4周。比较两组治疗前后血清胃泌素（GAS）、一氧化氮（NO）、生长激素释放多肽（Ghrelin）、瘦素（Leptin）和中医证候积分的变化,并比较治疗后粘膜愈合率及临床疗效。结果 治疗后,两组血清GAS、Ghrelin较治疗前均显著升高,血清NO、Leptin显著降低（P＜005）,观察组血清GAS、Ghrelin明显高于对照组,血清NO、Leptin明显比对照组低（P＜005）;治疗后,两组烧心、反酸、胸痛症状积分较治疗前均显著降低（P＜005）,观察组烧心、反酸、胸痛症状积分均明显比对照组低（P＜005）;观察组粘膜愈合率明显高于对照组（P＜005）;观察组临床总有效率明显高于对照组（P＜005）。结论 健胃愈疡片联合三联疗法治疗反流性食管炎效果显著,可有效促进食管粘膜愈合、缓解临床症状,促进临床疗效提高,可在临床推广应用。     

Assessing compressibility and compactibility of powder formulations with Near-Infrared Spectroscopy

Context: The compressibility and compatibility of a powder formulation is usually determined by compaction and following destructive tensile strength and relative density measurement of the final compact.

Objective: In this study, a non-destructive method with Near-Infrared Spectroscopy (NIRS) was designed and evaluated for the measurement of powder compressibility and compactibility.

Materials and Methods: 12 different formulations with a wide range of difference in properties were investigated by compaction and analysis of the resulting tablets. Two similar tablet batches were produced with every formulation. Relative density and tensile strength were measured with the traditional, destructive method on one tablet batch while a newly developed non-destructive chemometric NIRS method was applied for the second batch. The outcomes of the two approaches were compared to validate the developed method. All data sets were applied to three established mathematical equations to calculate equation factors, which are claimed to represent the formulation compressibility and compactibility. The study focus was set on the equation factor value comparison between the traditional and the newly designed method.

Results & Discussion: The results showed a high similarity between the outcomes of the two methods. An essential difference was noticed for the outcomes of the equation factors after application to the Leuenberger equation.

Conclusion: The approach with the NIRS is suggested as a promising tool for a reliable inline quality monitoring in the tablet manufacturing process.     

Enhanced dissolution of sildenafil citrate as dry foam tablets

Dry foam formulation technology is alternative approach to enhance dissolution of the drug. Sildenafil citrate was suspended in sodium dodecyl sulfate solution and adding a mixture of maltodextrin and mannitol as diluent to form a paste. Sildenafil citrate paste was passed through a nozzle spray bottle to obtain smooth foam. The homogeneous foam was dried in a vacuum oven and sieved to obtain dry foam granules. The granules were mixed with croscarmellose sodium, magnesium stearate and compressed into tablet. All formulations were evaluated for their physicochemical properties and dissolution profiles. All the tested excipients were compatible with sildenafil citrate by both differential scanning calorimetry (DSC) and infrared (IR) analysis. There are no X-ray diffraction (XRD) peaks representing crystals of sildenafil citrate observed form dry foam formulations. The hardness of tablets was about 5?kg, friability test <1% with a disintegration time <5?min. The sildenafil citrate dry foam tablet had higher dissolution rate in 0.1 N HCl in comparison with commercial sildenafil citrate tablet, sildenafil citrate prepared by direct compression and wet granulation method. Sildenafil citrate dry foam tablet with the high-level composition of surfactant, water and diluent showed enhanced dissolution rate than that of the lower-level composition of these excipients. This formulation was stable under accelerated conditions for at least 6 months.